Gracell Biotechnologies to Present Three Key Pipeline Updates at AACR 2026

April 2, 2026 - Grail Biotherapeutics (Beijing) Co., Ltd. ("Grail Bio"), a clinical-stage biotechnology company leading innovative immunotherapy, is pleased to announce that the company will present three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, to be held from April 17 to 22, 2026, at the San Diego Convention Center in California.

These three poster presentations will focus on introducing: 1) Updated clinical data and TCR clonal dynamic characteristics of GT201, a cytokine-enhanced tumor-infiltrating lymphocyte (TIL) product expressing membrane-bound IL-15 (“mbIL-15”); 2) The development, preclinical data, and preliminary clinical data of GT801, an innovative in vivo CAR-T candidate molecule targeting CD-19; and 3) Preliminary safety and efficacy data of GT719, an allogeneic CAR-iNKT cell therapy targeting CD19, which is generated through the in vitro differentiation of CD34+ hematopoietic stem cells derived from umbilical cord blood. Details of the reports are as follows:

Title:Armored TIL GT201 induces potent tumor-specific TCR expansion and durable antitumor responses in advanced solid tumor 

Meeting Category: Clinical Research

Conference Topic: Biomarkers Predictive of Therapeutic Benefit 5

Meeting Start Time: 4/21/2026 9:00:00 AM Local Time

End time of the meeting: 4/21/2026 12:00:00 PM Local Time

Location: Poster Section 42

Poster Board Number: 23

Poster Number: 5257

Title:In vivo CAR-T T-LNP system (GT801) drives potent B cell depletion and clinical feasibility in hematologic and autoimmune conditions

Meeting Category: Immunology

Conference Theme: Alternative Cell Type and In Situ Cell Therapies

Meeting Start Time: 4/19/2026 2:00:00 PM Local Time

End time of the meeting: 4/19/2026 5:00:00 PM local time

Location: Poster Section 7

Poster Board Number: 22

Poster Number: 148

Title:Stem cell-derived allogeneic anti-CD19 CAR-iNKT cell therapy GT719 for relapsed/refractory B cell malignancies

Meeting Classification: Clinical Research

Conference Theme: Adoptive Cell Therapy 1

Meeting Start Time: 4/20/2026 2:00:00 PM Local Time

End time of the meeting: 4/20/2026 5:00:00 PM local time

Location: Poster Section 40

Poster Board Number: 27

Poster Number: 3725

"We are excited to share the latest progress and data on GT201, GT801, and GT719. These programs collectively demonstrate Gracell Biotechnologies' comprehensive expertise in the field of cell therapy," said Dr. Yarong Liu, Founder and CEO of Gracell Biotechnologies. "This data represents another solid step in validating our technology platforms in TILs, allogeneic cell therapy, and in vivo CAR-T. We will continue to leverage our leadership position in cell therapy to bring innovative treatment options to patients with significant unmet medical needs."

Gracell Biotechnologies, founded in 2019, is an innovation-driven biopharmaceutical company in the late clinical stage.，Focused on pioneering the next generation of immunotherapies for cancer and autoimmune disease patients worldwide. With deep insights into the field of immunotherapy, cutting-edge R&D and technological platforms, and world-class manufacturing capabilities, Grit Biotechnology has established multiple self-developed technological platforms in China and the United States. It also boasts a diversified R&D pipeline containing several candidate products to address significant unmet clinical needs. GT101 Injection, independently developed by the company, is China’s first TIL drug approved for registrational clinical trials and is currently in a pivotal Phase II clinical trial. The self-developed GT201 Injection is the world’s first TIL product incorporating a membrane-bound IL-15 complex, which has completed dual IND submissions in China and the U.S. and has been approved to enter Phase I clinical trials. Additionally, the company has a highly innovative dual-gene knockout autologous TIL therapy, an mRNA vaccine targeting tumor neoantigens, the world’s first off-the-shelf CAR-iNKT cell therapy product derived from stem cells, and next-generation in vivo CAR-T therapies, forming a product portfolio encompassing pan-solid tumor TIL drugs and off-the-shelf cell therapies.